Market Size of Asia-Pacific Oral Anti-Diabetic Drug Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 25.37 Billion |
Market Size (2029) | USD 29.56 Billion |
CAGR (2024 - 2029) | 3.10 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Oral Anti-Diabetic Drug Market Analysis
The Asia-Pacific Oral Anti-Diabetic Drug Market size is estimated at USD 25.37 billion in 2024, and is expected to reach USD 29.56 billion by 2029, growing at a CAGR of 3.10% during the forecast period (2024-2029).
COVID-19 caused a gradual rise in demand for diabetes medications in the Asia-Pacific region. Patients with COVID-19 and pre-existing diabetes had blood glucose level changes, according to a study by BeatO in 2021 on 800 people, which finally resulted in a significant demand for cutting-edge medications to treat diabetes. In order to decrease the severe effects of COVID-19, Novo Nordisk has introduced a new social responsibility strategy to fight diabetes and give patients access to low-cost diabetes care in every nation.
Asian nations have seen a sharp rise in the number of people with diabetes over the past few decades, particularly those with type 2. More than 70% of people with diabetes live in developing nations. The Asia-Pacific region is expected to see significant growth as a result of an aging population and an increase in diabetes prevalence, which is mostly caused by increased stress levels, sedentary lifestyles, smoking, and excessive alcohol use that raises blood sugar levels. Also, the production infrastructure of some antidiabetic medicine manufacturers in the area contributed to the market expansion. However, one of the main commercial restraints is thought to be the rising cost of pharmaceuticals.
Biguanides, sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, glucosidase inhibitors are the main groups of oral antidiabetic drugs.